Chief Financial Officer, Sienna Biopharmaceuticals
John Smither served as Chief Financial Officer of Kythera Biopharmaceuticals, Inc. from November, 2007 until it was acquired by Allergan in October, 2015 for $2.1 billion. As CFO of Kythera, he was responsible for finance during multiple private and public capital raising rounds including the Company’s IPO and subsequent follow-on offerings, licensing and repurchasing of the international rights of its lead product to Bayer, and placement of several venture debt facilities. Mr. Smither also currently serves on the Board of Directors of Achaogen including as the Chair of the Audit Committee, and member of the Compensation Committee.
From 1998 to 2007, Mr. Smither held various positions at Amgen. From 2001 to 2004, Mr. Smither served as Vice President of Finance and Administration of Amgen’s European Division, where he was responsible for financial operations in 28 European countries. Prior to that role, Mr. Smither served as Head of Internal Audit, and following his time in Europe was Executive Director of Corporate Accounting at Amgen.
Prior to joining Amgen, Mr. Smither served as Audit Partner at Ernst & Young LLP, a public accounting firm, and following his time at Ernst & Young had served as the Chief Financial Officer of several early stage companies.
Mr. Smither received a BS in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.